China’s HLC, Panacea lead $100m funding in biotech startup Inmagene
Inmagene Biopharmaceuticals, a biotech startup with offices in China and the US, has closed $100 million in a Series C round of financing jointly led by health-focused HighLight Capital (HLC) and Panacea Venture, the startup announced in a WeChat post on Tuesday. The Series C round provided Inmagene – which is developing a pipeline of nearly 20 drug candidates for immunological […]
